Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Lexaria 將開始糖尿病和減肥動物研究 WEIGHT-A24-1
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested
Chronic dosing over a 12-week treatment period
Will assess weight loss and blood glucose level control
Efficacy through possible brain absorption delivery enhancement to be assessed
多種 Dehydratech-GLP-1 和 Dehydratech-CBD 配方有待測試
在 12 周的治療期內長期給藥
將評估體重減輕和血糖水平控制
通過可能增強大腦吸收傳遞的功效有待評估
KELOWNA, BC / ACCESSWIRE / March 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces details of an 8-week animal study WEIGHT-A24-1 (the "Study") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.
不列顛哥倫比亞省基洛納/ACCESSWIRE/2024年3月5日/藥物遞送平台領域的全球創新者Lexaria Bioscience Corp.（納斯達克股票代碼：LEXXW）（“公司” 或 “Lexaria”）公佈了一項爲期8周的動物研究 WEIGHT-A24-1（“研究”）的細節，該研究旨在研究脫水處理的胰高血糖素樣肽 1（“GLP-1”）對糖尿病和減肥的作用藥物和脫水劑加工的大麻二酚，單獨或聯合使用。
The contract for the Study has been awarded to...
該研究的合同已授予...
登入免費觀看全文
登入/註冊